CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Crenolanib besylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02400255
NCT02400255Phase 2Completed
CompareCT.gov

A Phase II Study of Crenolanib Besylate Maintenance Following Allogeneic Stem Cell Transplantation in Patients With FLT3-positive Acute Myeloid Leukemia

Arog Pharmaceuticals, Inc.·interventional·Posted Mar 27, 2015·Updated Dec 18, 2023

In Brief

A Phase 2 clinical trial evaluating Crenolanib besylate for Acute Myeloid Leukemia. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is a single-arm, Phase II study of crenolanib as maintenance in AML patients with FLT3 mutations who have achieved complete remission (CR) after allogeneic stem cell transplantation. Oral crenolanib will be administered daily post-transplant for up to two years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 27, 2015
Enrollment StartSep 1, 2015
Primary CompletionMay 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 11.3 years ago

Interventions

Crenolanib besylatedrug